Inactive Instrument

Polus BioPharm Inc. Stock

Equities

A007630

KR7007630007

Communications & Networking

Dynamic Chart
Polus BioPharm Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Polus BioPharm Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Polus BioPharm Inc.(KOSE:A007630) dropped from S&P Global BMI Index CI
POLUS BioPharm Inc. cancelled the acquisition of GTS Korea Co., Ltd. CI
Polus BioPharm Inc. announced that it expects to receive KRW 29.999999966 billion in funding from Polus Holdings Co., Ltd CI
Polus BioPharm Inc.(KOSE:A007630) added to S&P Global BMI Index CI
Polus Inc. announced that it has received KRW 18 billion in funding from POLUS BioPharm Inc. CI
Polus Inc. announced that it expects to receive KRW 18 billion in funding from POLUS BioPharm Inc. CI
Polus BioPharm Inc. announced that it has received KRW 19 billion in funding from Union Savings Bank, Yuil Pe Investment Co.,Ltd., Mason Capital Corporation, Sky Savings Bank, Ltd and other investors CI
POLUS BioPharm Inc. announced that it expects to receive KRW 18 billion in funding from Union Savings Bank, Youil PE Investment, Mason Capital Corporation, Sky Savings Bank, Ltd and another investor CI
POLUS BioPharm Inc. announced that it has received KRW 1.80000415 billion in funding CI
Polus Holdings Co., Ltd acquired additional stake in POLUS BioPharm Inc. from Akaglobal Co. Ltd., G & D Solution Co., Ltd. and PNA Bio Co., Ltd. CI
Polus Inc. announced that it has received KRW 25 billion in funding from Polus BioPharm Inc. CI
POLUS BioPharm Inc. agreed to acquire GTS Korea Co., Ltd. for KRW 3.6 billion. CI
POLUS BioPharm Inc. announced that it expects to receive KRW 1.80000415 billion in funding CI
More news
Managers TitleAgeSince
Chief Executive Officer 59 18-01-08
Comptroller/Controller/Auditor 60 18-01-08
Comptroller/Controller/Auditor 59 16-07-13
Members of the board TitleAgeSince
Director/Board Member 60 -
Chief Executive Officer 59 18-01-08
Corporate Officer/Principal 72 16-07-13
More insiders
POLUS BioPharm Inc., formerly AMNIS CO., LTD, is a Korea-based company mainly engaged in the manufacture and distribution of communications equipment. The Company operates its business through Communications Equipment Segment, Electronic Measuring Instrument Segment and Other Segment. Its Communications Equipment Segment mainly manufactures repeaters under the brand name of GSI. Its Electronic Measuring Instrument Segment mainly manufactures electronic measuring instruments under the brand name of Protek, and its Other Segment mainly provides communication related services. The Company distributes its products within domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. A007630 Stock